[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-001", "question": "A 28-year-old male with a history of opioid use disorder presents with syncope. He admits to taking 'massive doses' of an over-the-counter anti-diarrheal medication to manage withdrawal symptoms. ECG shows sinus bradycardia at 45 bpm, a QTc interval of 680 ms, and intermittent broad-complex beats. He is hemodynamically stable but lethargic. Magnesium sulfate 2g IV is administered without change in the rhythm. Which of the following is the most appropriate next step in management?", "options": ["Option A: IV Amiodarone infusion", "Option B: IV Isoproterenol infusion", "Option C: IV Physostigmine", "Option D: Synchronized cardioversion", "Option E: IV Calcium gluconate"], "answer": "B", "answer_index": 1, "explanation": "The patient has loperamide toxicity, which blocks cardiac sodium and potassium channels, causing QTc prolongation and wide-complex dysrhythmias. Unlike congenital Long QT (where isoproterenol is contraindicated), loperamide-induced TdP/QT prolongation is bradycardia-dependent; increasing the heart rate (chemical or electrical overdrive pacing) shortens the QT interval and prevents Torsades de Pointes. Amiodarone prolongs QT and is contraindicated.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The clinical problem is managing persistent bradycardia-dependent QT prolongation and dysrhythmias due to loperamide toxicity after magnesium fails. Key stem clues: 28-year-old with opioid use disorder ingesting massive OTC anti-diarrheal (implying loperamide), syncope, ECG with sinus bradycardia (45 bpm), QTc 680 ms, intermittent broad-complex beats, hemodynamic stability but lethargy, no response to IV magnesium. These imply loperamide-induced cardiac toxicity (Na/K channel blockade) causing bradycardia-dependent Torsades de Pointes risk. Keyed answer B (IV Isoproterenol) fits as it increases heart rate, shortens QT, and prevents TdP recurrence, per toxicology guidelines. Alternatives: A (Amiodarone) worsens QT prolongation; C (Physostigmine) is for anticholinergic toxicity, irrelevant here; D (Synchronized cardioversion) is for unstable rhythms, but patient is stable; E (IV Calcium) addresses calcium channel blockade or hyperkalemia, not primary here. No main logical issues; stem supports unique best answer without contradictions or underspecification. No main medical accuracy issues; aligns with current standards for acquired, drug-induced LQTS management (e.g., ACLS/toxicology protocols favoring overdrive for refractory cases). Minimal fix: None required; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The clinical problem is managing persistent bradycardia-dependent QT prolongation and dysrhythmias due to loperamide toxicity after magnesium fails. Key stem clues: 28-year-old with opioid use disorder ingesting massive OTC anti-diarrheal (implying loperamide), syncope, ECG with sinus bradycardia (45 bpm), QTc 680 ms, intermittent broad-complex beats, hemodynamic stability but lethargy, no response to IV magnesium. These imply loperamide-induced cardiac toxicity (Na/K channel blockade) causing bradycardia-dependent Torsades de Pointes risk. Keyed answer B (IV Isoproterenol) fits as it increases heart rate, shortens QT, and prevents TdP recurrence, per toxicology guidelines. Alternatives: A (Amiodarone) worsens QT prolongation; C (Physostigmine) is for anticholinergic toxicity, irrelevant here; D (Synchronized cardioversion) is for unstable rhythms, but patient is stable; E (IV Calcium) addresses calcium channel blockade or hyperkalemia, not primary here. No main logical issues; stem supports unique best answer without contradictions or underspecification. No main medical accuracy issues; aligns with current standards for acquired, drug-induced LQTS management (e.g., ACLS/toxicology protocols favoring overdrive for refractory cases). Minimal fix: None required; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-002", "question": "A 4-month-old female presents with failure to thrive, hypotonia, and a history of pyridoxine-responsive seizures. Laboratory evaluation reveals hypercalcemia, hypercalciuria, and a suppressed parathyroid hormone (PTH) level. Skeletal survey demonstrates diffuse demineralization and 'moth-eaten' radiolucencies at the metaphyses. Serum alkaline phosphatase (ALP) is 15 IU/L (Reference: 150-420 IU/L). Which of the following is the definitive treatment for this condition?", "options": ["Option A: High-dose Vitamin D supplementation", "Option B: Recombinant human parathyroid hormone (Teriparatide)", "Option C: Asfotase alfa", "Option D: Pyridoxine (Vitamin B6) monotherapy", "Option E: Bisphosphonate therapy"], "answer": "C", "answer_index": 2, "explanation": "The diagnosis is Hypophosphatasia (HPP), caused by a loss-of-function mutation in the ALPL gene encoding tissue-nonspecific alkaline phosphatase (TNSALP). Low ALP leads to accumulation of inorganic pyrophosphate (an inhibitor of bone mineralization) and pyridoxal-5'-phosphate (causing B6-dependent seizures due to lack of dephosphorylation). Asfotase alfa is the enzyme replacement therapy. Vitamin D and bisphosphonates are contraindicated as they may worsen hypercalcemia and inhibit mineralization further.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The clinical problem is identifying the definitive treatment for an infant with failure to thrive, hypotonia, pyridoxine-responsive seizures, hypercalcemia, hypercalciuria, suppressed PTH, low ALP (15 IU/L), and skeletal demineralization with metaphyseal radiolucencies. Key stem clues driving unique best answer: low ALP with hypercalcemia/hypercalciuria and suppressed PTH (suggests impaired mineralization due to ALP deficiency); pyridoxine-responsive seizures (due to accumulated pyridoxal-5'-phosphate); bone findings consistent with hypophosphatasia (HPP). Most likely diagnosis: Infantile HPP from ALPL mutation. Keyed answer C (Asfotase alfa) fits as enzyme replacement therapy addressing TNSALP deficiency, improving mineralization and seizures. Alternatives: A (High-dose Vitamin D) worsens hypercalcemia; B (Teriparatide) irrelevant for HPP, used in osteoporosis; D (Pyridoxine monotherapy) treats seizures but not underlying mineralization defect; E (Bisphosphonate) contraindicated, may inhibit mineralization further. No main logical issues; stem allows discrimination of single best option without contradictions or underspecification. No main medical accuracy issues; aligns with current guidelines (e.g., Asfotase alfa approved for perinatal/infantile HPP since 2015, contraindications accurate). Minimal fix: No edit required; item is unambiguous and accurate as is.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The clinical problem is identifying the definitive treatment for an infant with failure to thrive, hypotonia, pyridoxine-responsive seizures, hypercalcemia, hypercalciuria, suppressed PTH, low ALP (15 IU/L), and skeletal demineralization with metaphyseal radiolucencies. Key stem clues driving unique best answer: low ALP with hypercalcemia/hypercalciuria and suppressed PTH (suggests impaired mineralization due to ALP deficiency); pyridoxine-responsive seizures (due to accumulated pyridoxal-5'-phosphate); bone findings consistent with hypophosphatasia (HPP). Most likely diagnosis: Infantile HPP from ALPL mutation. Keyed answer C (Asfotase alfa) fits as enzyme replacement therapy addressing TNSALP deficiency, improving mineralization and seizures. Alternatives: A (High-dose Vitamin D) worsens hypercalcemia; B (Teriparatide) irrelevant for HPP, used in osteoporosis; D (Pyridoxine monotherapy) treats seizures but not underlying mineralization defect; E (Bisphosphonate) contraindicated, may inhibit mineralization further. No main logical issues; stem allows discrimination of single best option without contradictions or underspecification. No main medical accuracy issues; aligns with current guidelines (e.g., Asfotase alfa approved for perinatal/infantile HPP since 2015, contraindications accurate). Minimal fix: No edit required; item is unambiguous and accurate as is.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-003", "question": "A 68-year-old male presents with recurrent fevers, painful auricular chondritis, pulmonary infiltrates, and macrocytic anemia. He has been treated for 'refractory relapsing polychondritis' without success. Bone marrow biopsy reveals hypercellularity with prominent cytoplasmic vacuoles in myeloid and erythroid precursor cells. Which of the following is the most likely diagnosis?", "options": ["Option A: Myelodysplastic Syndrome (MDS) with excess blasts", "Option B: VEXAS syndrome", "Option C: Sweet syndrome", "Option D: Polyarteritis Nodosa", "Option E: Granulomatosis with Polyangiitis"], "answer": "B", "answer_index": 1, "explanation": "VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently described disorder caused by somatic mutations in the UBA1 gene. It presents in older men with inflammatory features (chondritis, vasculitis, fevers) and hematologic abnormalities (macrocytic anemia). The pathognomonic finding is vacuoles in myeloid and erythroid precursors in the bone marrow.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent fevers, painful auricular chondritis, pulmonary infiltrates, macrocytic anemia, unsuccessful treatment for refractory relapsing polychondritis, and bone marrow hypercellularity with prominent cytoplasmic vacuoles in myeloid and erythroid precursors. These findings collectively point to VEXAS syndrome as the most likely diagnosis, with vacuoles being pathognomonic in this context of autoinflammatory features in an older male. Main logical issue(s): None; the stem provides sufficient discriminating details to identify a single best answer without contradictions or underspecification, as alternatives do not fully match the combination of hematologic and inflammatory manifestations. Main medical accuracy issue(s): None; the item's portrayal of VEXAS syndrome aligns with current medical consensus (e.g., NEJM 2020 description), including somatic UBA1 mutations causing vacuolization and macrocytic anemia alongside chondritis and fevers. Alternatives are appropriately distractors: MDS may show vacuoles but lacks prominent inflammatory features; Sweet syndrome involves neutrophilic infiltrates without specific BM vacuoles or chondritis; PAN and GPA are vasculitides but do not feature the hematologic profile or pathognomonic BM findings. Minimal fix: None needed; item is unambiguous and accurate as is.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent fevers, painful auricular chondritis, pulmonary infiltrates, macrocytic anemia, unsuccessful treatment for refractory relapsing polychondritis, and bone marrow hypercellularity with prominent cytoplasmic vacuoles in myeloid and erythroid precursors. These findings collectively point to VEXAS syndrome as the most likely diagnosis, with vacuoles being pathognomonic in this context of autoinflammatory features in an older male. Main logical issue(s): None; the stem provides sufficient discriminating details to identify a single best answer without contradictions or underspecification, as alternatives do not fully match the combination of hematologic and inflammatory manifestations. Main medical accuracy issue(s): None; the item's portrayal of VEXAS syndrome aligns with current medical consensus (e.g., NEJM 2020 description), including somatic UBA1 mutations causing vacuolization and macrocytic anemia alongside chondritis and fevers. Alternatives are appropriately distractors: MDS may show vacuoles but lacks prominent inflammatory features; Sweet syndrome involves neutrophilic infiltrates without specific BM vacuoles or chondritis; PAN and GPA are vasculitides but do not feature the hematologic profile or pathognomonic BM findings. Minimal fix: None needed; item is unambiguous and accurate as is.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-004", "question": "A 55-year-old female with chronic malnutrition and a history of chronic acetaminophen use for osteoarthritis presents with altered mental status. Arterial blood gas shows pH 7.28, pCO2 28 mmHg, HCO3 12 mEq/L. The anion gap is 24. Lactate is 0.9 mmol/L, serum ketones are negative, and creatinine is 1.1 mg/dL. Toxic alcohol screen is negative. Which of the following is the most appropriate therapeutic intervention?", "options": ["Option A: IV Fomepizole", "Option B: IV Sodium Bicarbonate", "Option C: N-acetylcysteine", "Option D: Hemodialysis", "Option E: Thiamine and Dextrose"], "answer": "C", "answer_index": 2, "explanation": "This patient has high anion gap metabolic acidosis due to 5-oxoproline (pyroglutamic acid) accumulation. This occurs in the setting of glutathione depletion (malnutrition, acetaminophen use), which disrupts the gamma-glutamyl cycle. N-acetylcysteine replenishes glutathione stores, restoring the feedback loop and halting 5-oxoproline production. Fomepizole is for toxic alcohols, which were ruled out.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Chronic malnutrition and acetaminophen use suggest glutathione depletion leading to 5-oxoproline (pyroglutamic) acidosis, presenting as high anion gap metabolic acidosis (AG 24, pH 7.28, HCO3 12) with altered mental status; normal lactate, negative ketones, normal creatinine, and negative toxic alcohol screen rule out common differentials like lactic acidosis, ketoacidosis, renal failure, and toxic alcohols. Main logical issue(s): None; the vignette provides sufficient discriminating findings to identify pyroglutamic acidosis as the most likely cause, making N-acetylcysteine (NAC) the unique best intervention by replenishing glutathione and halting 5-oxoproline accumulation. Alternatives are inferior: Fomepizole targets ruled-out toxic alcohols; sodium bicarbonate addresses acidosis symptomatically but not the cause; hemodialysis is for severe/refractory cases, not first-line; thiamine/dextrose suits nutritional deficiencies but doesn't target the metabolic pathway. Main medical accuracy issue(s): None; aligns with current understanding of pyroglutamic acidosis pathophysiology and NAC's role in glutathione restoration, per mainstream medical literature (e.g., case reports in NEJM, Annals). Minimal fix: None needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Chronic malnutrition and acetaminophen use suggest glutathione depletion leading to 5-oxoproline (pyroglutamic) acidosis, presenting as high anion gap metabolic acidosis (AG 24, pH 7.28, HCO3 12) with altered mental status; normal lactate, negative ketones, normal creatinine, and negative toxic alcohol screen rule out common differentials like lactic acidosis, ketoacidosis, renal failure, and toxic alcohols. Main logical issue(s): None; the vignette provides sufficient discriminating findings to identify pyroglutamic acidosis as the most likely cause, making N-acetylcysteine (NAC) the unique best intervention by replenishing glutathione and halting 5-oxoproline accumulation. Alternatives are inferior: Fomepizole targets ruled-out toxic alcohols; sodium bicarbonate addresses acidosis symptomatically but not the cause; hemodialysis is for severe/refractory cases, not first-line; thiamine/dextrose suits nutritional deficiencies but doesn't target the metabolic pathway. Main medical accuracy issue(s): None; aligns with current understanding of pyroglutamic acidosis pathophysiology and NAC's role in glutathione restoration, per mainstream medical literature (e.g., case reports in NEJM, Annals). Minimal fix: None needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-005", "question": "A 32-year-old female presents with amenorrhea and galactorrhea. MRI reveals a 4.5 cm pituitary macroadenoma with invasion into the cavernous sinus. Visual fields are intact. Serum prolactin is reported as 145 ng/mL (Reference: <25 ng/mL). Which of the following is the most appropriate next step in management?", "options": ["Option A: Referral for transsphenoidal resection", "Option B: Stereotactic radiosurgery", "Option C: Measurement of prolactin in diluted serum", "Option D: Octreotide scintigraphy", "Option E: Bilateral inferior petrosal sinus sampling"], "answer": "C", "answer_index": 2, "explanation": "A 4.5 cm prolactinoma should typically produce prolactin levels >1,000-10,000 ng/mL. A mildly elevated level in the setting of a giant adenoma suggests the 'Hook Effect,' where excessive antigen saturates the assay antibodies, preventing sandwich formation and leading to a falsely low result. Diluting the sample (1:100) reveals the true elevated value. Confirming a prolactinoma is crucial because dopamine agonists (cabergoline) are the first-line treatment, not surgery.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include a 32-year-old female with amenorrhea and galactorrhea, a 4.5 cm pituitary macroadenoma invading the cavernous sinus, intact visual fields, and serum prolactin of 145 ng/mL (reference <25 ng/mL). These suggest a prolactinoma, but the prolactin level is disproportionately low for the tumor size, pointing to the hook effect artifact in immunoassays. The question asks for the most appropriate next step, and option C (measurement of prolactin in diluted serum) directly addresses confirming the true prolactin level to verify prolactinoma diagnosis before considering dopamine agonist therapy as first-line management. Alternatives are inferior: A (transsphenoidal resection) is not first-line for prolactinomas without compressive symptoms; B (stereotactic radiosurgery) is adjunctive, not initial; D (octreotide scintigraphy) assesses somatostatin receptors, irrelevant here; E (bilateral inferior petrosal sinus sampling) is for ACTH-dependent Cushing's differentiation, not applicable. No main logical issues; the stem provides sufficient details for discriminating a single best answer without contradictions or underspecification. No main medical accuracy issues; aligns with standard endocrinology knowledge on hook effect in large prolactinomas and guideline-based management (dopamine agonists preferred over surgery for non-compressive cases). Minimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include a 32-year-old female with amenorrhea and galactorrhea, a 4.5 cm pituitary macroadenoma invading the cavernous sinus, intact visual fields, and serum prolactin of 145 ng/mL (reference <25 ng/mL). These suggest a prolactinoma, but the prolactin level is disproportionately low for the tumor size, pointing to the hook effect artifact in immunoassays. The question asks for the most appropriate next step, and option C (measurement of prolactin in diluted serum) directly addresses confirming the true prolactin level to verify prolactinoma diagnosis before considering dopamine agonist therapy as first-line management. Alternatives are inferior: A (transsphenoidal resection) is not first-line for prolactinomas without compressive symptoms; B (stereotactic radiosurgery) is adjunctive, not initial; D (octreotide scintigraphy) assesses somatostatin receptors, irrelevant here; E (bilateral inferior petrosal sinus sampling) is for ACTH-dependent Cushing's differentiation, not applicable. No main logical issues; the stem provides sufficient details for discriminating a single best answer without contradictions or underspecification. No main medical accuracy issues; aligns with standard endocrinology knowledge on hook effect in large prolactinomas and guideline-based management (dopamine agonists preferred over surgery for non-compressive cases). Minimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-006", "question": "A 60-year-old male with a history of radiation therapy for Hodgkin lymphoma presents with signs of cardiac tamponade. Pericardiocentesis is performed, draining 800 mL of bloody fluid. Following drainage, the intrapericardial pressure drops to 0 mmHg, but the right atrial pressure remains elevated at 18 mmHg with a prominent y-descent that was previously absent. Which of the following is the most likely diagnosis?", "options": ["Option A: Incomplete drainage of the effusion", "Option B: Effusive-constrictive pericarditis", "Option C: Right ventricular infarction", "Option D: Pulmonary embolism", "Option E: Flash pulmonary edema"], "answer": "B", "answer_index": 1, "explanation": "Effusive-constrictive pericarditis is characterized by concurrent tamponade and constriction. The visceral pericardium is thickened and constrictive. Initially, the effusion masks the constriction (tamponade physiology: blunted y-descent). After drainage, the tamponade resolves, but the underlying constriction becomes manifest (elevated RA pressure with prominent y-descent). Treatment requires visceral pericardiectomy.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include history of radiation therapy for Hodgkin lymphoma (risk factor for pericardial disease), presentation with cardiac tamponade, drainage of 800 mL bloody fluid with normalization of intrapericardial pressure to 0 mmHg, but persistent elevation of right atrial pressure at 18 mmHg with a newly prominent y-descent (previously absent). These findings point to effusive-constrictive pericarditis, where the effusion initially masks underlying visceral pericardial constriction; post-drainage, constriction manifests with elevated RA pressure and prominent y-descent. Main logical issue(s): None; the stem provides sufficient discriminating details (e.g., normal intrapericardial pressure rules out incomplete drainage, new y-descent post-drainage supports constriction over other options like RV infarction or PE, which lack this temporal link). Main medical accuracy issue(s): None; aligns with established pathophysiology of effusive-constrictive pericarditis, common post-radiation, per cardiology guidelines (e.g., ACC/AHA). The item's logic is sound, with no inaccuracies in associations or management implications. Minimal fix: None needed; item is already unambiguous and accurate, though adding 'visceral pericardial thickening on imaging' could enhance realism if desired, but not required.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include history of radiation therapy for Hodgkin lymphoma (risk factor for pericardial disease), presentation with cardiac tamponade, drainage of 800 mL bloody fluid with normalization of intrapericardial pressure to 0 mmHg, but persistent elevation of right atrial pressure at 18 mmHg with a newly prominent y-descent (previously absent). These findings point to effusive-constrictive pericarditis, where the effusion initially masks underlying visceral pericardial constriction; post-drainage, constriction manifests with elevated RA pressure and prominent y-descent. Main logical issue(s): None; the stem provides sufficient discriminating details (e.g., normal intrapericardial pressure rules out incomplete drainage, new y-descent post-drainage supports constriction over other options like RV infarction or PE, which lack this temporal link). Main medical accuracy issue(s): None; aligns with established pathophysiology of effusive-constrictive pericarditis, common post-radiation, per cardiology guidelines (e.g., ACC/AHA). The item's logic is sound, with no inaccuracies in associations or management implications. Minimal fix: None needed; item is already unambiguous and accurate, though adding 'visceral pericardial thickening on imaging' could enhance realism if desired, but not required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-007", "question": "A 65-year-old male is admitted to the ICU for sedation and mechanical ventilation. On day 3 of a continuous propofol infusion, he develops new Right Bundle Branch Block with coved ST-segment elevation in leads V1-V3. Labs reveal severe metabolic acidosis (pH 7.18), Lactate 9 mmol/L, and CK 8,000 U/L. Echocardiogram shows new global hypokinesis. Which of the following is the most likely diagnosis?", "options": ["Option A: Acute Anterior ST-Elevation MI", "Option B: Massive Pulmonary Embolism", "Option C: Propofol Infusion Syndrome", "Option D: Brugada Syndrome unmasked by fever", "Option E: Septic Cardiomyopathy"], "answer": "C", "answer_index": 2, "explanation": "Propofol Infusion Syndrome (PRIS) is a rare but lethal complication of high-dose/long-duration propofol. It causes mitochondrial failure leading to rhabdomyolysis, metabolic acidosis, heart failure, and characteristic ECG changes (often Brugada-like pattern: RBBB with coved ST elevation). Immediate cessation of propofol and supportive care is required.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Continuous propofol infusion on day 3, new RBBB with coved ST elevation in V1-V3, severe metabolic acidosis (pH 7.18), elevated lactate (9 mmol/L) and CK (8,000 U/L), and echocardiogram showing new global hypokinesis. These findings collectively point to Propofol Infusion Syndrome (PRIS), a rare complication involving mitochondrial dysfunction, rhabdomyolysis, acidosis, and Brugada-like ECG changes. Main logical issue(s): None; the vignette provides sufficient discriminating details to identify C as the single best answer without contradictions or underspecification. Alternatives are inferior: A (MI) typically shows regional wall motion abnormalities, not global; B (PE) may cause RV strain but not rhabdomyolysis or high CK; D (Brugada) requires fever, which is absent; E (septic cardiomyopathy) lacks specific propofol association and Brugada pattern. Main medical accuracy issue(s): None; aligns with established knowledge of PRIS, including mitochondrial failure leading to the described features, consistent with critical care guidelines. Minimal fix: Not needed, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Continuous propofol infusion on day 3, new RBBB with coved ST elevation in V1-V3, severe metabolic acidosis (pH 7.18), elevated lactate (9 mmol/L) and CK (8,000 U/L), and echocardiogram showing new global hypokinesis. These findings collectively point to Propofol Infusion Syndrome (PRIS), a rare complication involving mitochondrial dysfunction, rhabdomyolysis, acidosis, and Brugada-like ECG changes. Main logical issue(s): None; the vignette provides sufficient discriminating details to identify C as the single best answer without contradictions or underspecification. Alternatives are inferior: A (MI) typically shows regional wall motion abnormalities, not global; B (PE) may cause RV strain but not rhabdomyolysis or high CK; D (Brugada) requires fever, which is absent; E (septic cardiomyopathy) lacks specific propofol association and Brugada pattern. Main medical accuracy issue(s): None; aligns with established knowledge of PRIS, including mitochondrial failure leading to the described features, consistent with critical care guidelines. Minimal fix: Not needed, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-008", "question": "A 58-year-old male with dyslipidemia develops proximal muscle weakness and myalgias. His CK is 8,500 U/L. Atorvastatin is discontinued. Two months later, his weakness has progressed, and CK remains elevated at 9,200 U/L. Muscle biopsy shows necrotizing myopathy with minimal inflammation. Testing for anti-HMGCR antibodies is positive. Which of the following is the most appropriate management?", "options": ["Option A: Switch to Rosuvastatin", "Option B: Initiate Coenzyme Q10 supplementation", "Option C: Initiate IVIG and/or systemic immunosuppression", "Option D: Observation for spontaneous resolution", "Option E: Dantrolene sodium"], "answer": "C", "answer_index": 2, "explanation": "This patient has Statin-Associated Autoimmune Myopathy (SAAM), specifically anti-HMGCR positive necrotizing myopathy. Unlike self-limited statin myotoxicity, this is an autoimmune process that progresses despite statin cessation. It requires aggressive immunosuppression (steroids, IVIG, Rituximab, or Methotrexate) to prevent permanent muscle loss.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include proximal muscle weakness and myalgias post-atorvastatin, elevated CK persisting and rising to 9,200 U/L despite discontinuation, muscle biopsy showing necrotizing myopathy with minimal inflammation, and positive anti-HMGCR antibodies, indicating statin-associated autoimmune myopathy (SAAM). These findings imply an ongoing autoimmune process requiring active intervention, making C (IVIG and/or systemic immunosuppression) the single best management per standard guidelines. Main logical issue(s): None; the vignette provides sufficient discriminating details without contradictions, allowing clear differentiation—e.g., progression rules out D (observation), another statin (A) could exacerbate, CoQ10 (B) addresses non-autoimmune myotoxicity, and dantrolene (E) is irrelevant for this pathophysiology. Main medical accuracy issue(s): None; aligns with current rheumatology consensus on anti-HMGCR necrotizing myopathy, where immunosuppression (e.g., steroids, IVIG, rituximab) is essential to halt progression and prevent disability, consistent with USMLE-level knowledge and major guidelines like those from the American College of Rheumatology. Minimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include proximal muscle weakness and myalgias post-atorvastatin, elevated CK persisting and rising to 9,200 U/L despite discontinuation, muscle biopsy showing necrotizing myopathy with minimal inflammation, and positive anti-HMGCR antibodies, indicating statin-associated autoimmune myopathy (SAAM). These findings imply an ongoing autoimmune process requiring active intervention, making C (IVIG and/or systemic immunosuppression) the single best management per standard guidelines. Main logical issue(s): None; the vignette provides sufficient discriminating details without contradictions, allowing clear differentiation—e.g., progression rules out D (observation), another statin (A) could exacerbate, CoQ10 (B) addresses non-autoimmune myotoxicity, and dantrolene (E) is irrelevant for this pathophysiology. Main medical accuracy issue(s): None; aligns with current rheumatology consensus on anti-HMGCR necrotizing myopathy, where immunosuppression (e.g., steroids, IVIG, rituximab) is essential to halt progression and prevent disability, consistent with USMLE-level knowledge and major guidelines like those from the American College of Rheumatology. Minimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-009", "question": "A 2-week-old XX infant presents with ambiguous genitalia (virilization). Vital signs reveal a blood pressure of 96/60 mmHg (hypertensive for age). Laboratory evaluation shows Sodium 136 mEq/L and Potassium 2.9 mEq/L. 17-hydroxyprogesterone is elevated. Which of the following enzyme deficiencies is the most likely cause?", "options": ["Option A: 21-hydroxylase deficiency", "Option B: 11-beta-hydroxylase deficiency", "Option C: 17-alpha-hydroxylase deficiency", "Option D: 3-beta-hydroxysteroid dehydrogenase deficiency", "Option E: P450 oxidoreductase deficiency"], "answer": "B", "answer_index": 1, "explanation": "Congenital Adrenal Hyperplasia due to 11-beta-hydroxylase deficiency blocks cortisol synthesis, shunting precursors to androgens (causing virilization in females) and accumulating 11-deoxycorticosterone (DOC). DOC is a potent mineralocorticoid, leading to salt retention, hypertension, and hypokalemia. This distinguishes it from the more common 21-hydroxylase deficiency, which causes salt-wasting (hypotension, hyperkalemia).", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include virilization in an XX infant (androgen excess), hypertension (mineralocorticoid excess), hypokalemia (potassium wasting), normal sodium, and elevated 17-hydroxyprogesterone (consistent with CAH). These findings point to 11-beta-hydroxylase deficiency, where blocked cortisol synthesis leads to androgen shunting and DOC accumulation, causing hypertension and hypokalemia, distinguishing it from salt-wasting forms. Main logical issue(s): None; the stem provides sufficient discriminating details (e.g., hypertension and hypokalemia vs. expected hypotension/hyperkalemia in 21-hydroxylase) to support B as the unique best without contradictions or underspecification. Options are comparable enzyme deficiencies in steroidogenesis, allowing clear discrimination. Main medical accuracy issue(s): None; aligns with standard pathophysiology of CAH variants per endocrine guidelines (e.g., Endocrine Society), including virilization in females with 11-beta deficiency, elevated 17-OHP, and mineralocorticoid effects of DOC. This is board-relevant and realistic. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include virilization in an XX infant (androgen excess), hypertension (mineralocorticoid excess), hypokalemia (potassium wasting), normal sodium, and elevated 17-hydroxyprogesterone (consistent with CAH). These findings point to 11-beta-hydroxylase deficiency, where blocked cortisol synthesis leads to androgen shunting and DOC accumulation, causing hypertension and hypokalemia, distinguishing it from salt-wasting forms. Main logical issue(s): None; the stem provides sufficient discriminating details (e.g., hypertension and hypokalemia vs. expected hypotension/hyperkalemia in 21-hydroxylase) to support B as the unique best without contradictions or underspecification. Options are comparable enzyme deficiencies in steroidogenesis, allowing clear discrimination. Main medical accuracy issue(s): None; aligns with standard pathophysiology of CAH variants per endocrine guidelines (e.g., Endocrine Society), including virilization in females with 11-beta deficiency, elevated 17-OHP, and mineralocorticoid effects of DOC. This is board-relevant and realistic. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-010", "question": "A 45-year-old male on chronic amiodarone therapy for atrial fibrillation presents with weight loss and palpitations. TSH is <0.01 mIU/L and Free T4 is elevated. He has no neck pain. Thyroid ultrasound with color flow Doppler reveals an absence of vascularity within the thyroid parenchyma. Which of the following is the most appropriate initial treatment?", "options": ["Option A: Methimazole", "Option B: Propylthiouracil", "Option C: Prednisone", "Option D: Radioactive Iodine ablation", "Option E: Potassium Perchlorate"], "answer": "C", "answer_index": 2, "explanation": "This is Type 2 Amiodarone-Induced Thyrotoxicosis (AIT), which is a destructive thyroiditis caused by direct cytotoxic effects of the drug. The key differentiator from Type 1 AIT (Jod-Basedow/iodine-induced synthesis) is the Doppler flow: Type 1 has increased vascularity, while Type 2 has absent vascularity. Type 2 is treated with high-dose glucocorticoids. Thionamides (Methimazole) are ineffective for destructive thyroiditis.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Chronic amiodarone therapy, symptoms of thyrotoxicosis (weight loss, palpitations), suppressed TSH with elevated Free T4, no neck pain, and thyroid ultrasound showing absent vascularity, pointing to Type 2 amiodarone-induced thyrotoxicosis (AIT) due to destructive thyroiditis rather than Type 1 (iodine-induced hyperthyroidism). These clues differentiate Type 2 (absent flow, steroid-responsive) from Type 1 (increased flow, thionamide-responsive). Main logical issue(s), if any: None; the vignette provides sufficient discriminating details for a single best answer without contradictions or underspecification. Main medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., Endocrine Society) where Type 2 AIT is initially treated with glucocorticoids like prednisone, while thionamides (A, B) are ineffective for destructive processes, RAI (D) is not first-line and contraindicated in active inflammation, and perchlorate (E) is adjunctive for Type 1. The item's logic correctly associates absent vascularity with Type 2 and steroid therapy. Minimal fix: Not needed, as the item is already unambiguous and accurate; however, adding 'high-dose' to option C could enhance precision without altering intent.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Chronic amiodarone therapy, symptoms of thyrotoxicosis (weight loss, palpitations), suppressed TSH with elevated Free T4, no neck pain, and thyroid ultrasound showing absent vascularity, pointing to Type 2 amiodarone-induced thyrotoxicosis (AIT) due to destructive thyroiditis rather than Type 1 (iodine-induced hyperthyroidism). These clues differentiate Type 2 (absent flow, steroid-responsive) from Type 1 (increased flow, thionamide-responsive). Main logical issue(s), if any: None; the vignette provides sufficient discriminating details for a single best answer without contradictions or underspecification. Main medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., Endocrine Society) where Type 2 AIT is initially treated with glucocorticoids like prednisone, while thionamides (A, B) are ineffective for destructive processes, RAI (D) is not first-line and contraindicated in active inflammation, and perchlorate (E) is adjunctive for Type 1. The item's logic correctly associates absent vascularity with Type 2 and steroid therapy. Minimal fix: Not needed, as the item is already unambiguous and accurate; however, adding 'high-dose' to option C could enhance precision without altering intent.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]